- Antiviral Drugs
- Immunosuppressant’s
- Vaccines
- Immunoglobulin’s
- Corticosteroids,
- Targeted Therapy
- Chemotherapy
Chronic Liver Disease Market was valued at USD 22,143 million in 2022 and is poised to grow at a CAGR of 7% over 2023-2029. Chronic liver disease is a process of progressive liver destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis that consists of liver pathologies including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Based on the treatment type, the antiviral drugs segment is anticipated to dominate the market share over the forecast period. According to the study, Burden of Liver Diseases in the World, issued in 2019, globally, liver disorders account for about 2 million deaths per year, of which 1 million are due to viral hepatocellular carcinoma, and hepatitis, and the rest of the 1 million deaths are owing to the complications of cirrhosis. The increasing prevalence and incidences of chronic liver diseases and increasing product launches and approvals will act as the chronic liver disease market growth drivers and the high cost of diagnostic devices will be the lagging factor for the market. The emerging markets, increase in unmet healthcare needs, and improved healthcare infrastructure are the opportunities for players in the market.
Chronic Liver Disease Market Key Developments:
- In Sep 2021, Mirum Pharmaceuticals received the US FDA approval for Livmari (Malalixibat) oral solution for the treatment of cholestatic pruritis in patients with Allagile Syndrome.
- In Jan 2022, Merck received conditional liver cancer treatment approval for its drug Keytruda based on its second confirmatory study.
Chronic Liver Disease Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
7%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Chronic Liver Disease Market Dynamics
Development of government and non-government awareness programs are driving the market growth. For instance, in Jan 2023, the International Liver Transplantation Study Group and the Liver Transplant Society of India held Asia’s first consensus conference on patient care for small liver grafts in India. Thus, the increased awareness, research, and development for liver disorders will lead to the growth of the market within the forecast period, whereas, the lack of skilled professionals, and complexity associated with liver diagnostic systems will have a negative impact on the market growth.
North-America Got Significant Share of
Chronic Liver Disease Market Regional Analysis
According to a research study published in the Clinical liver disease journal, 1.5 billion people, globally, are affected by chronic liver disease. As per the American Association for the Study of Liver Diseases Publication, the most common cause of chronic liver diseases, such as non-alcoholic fatty liver disease, had a prevalence of 59%, 29% for hepatitis B, 9% for hepatitis C, and 2% for alcoholic liver disease. The North America Chronic Liver Disease market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players. The Asia Pacific region is also expected to witness significant growth owing to an increase in alcohol consumption and high disease prevalence. The European chronic liver disease market is growing at a faster rate due to the increased prevalence of the liver disease population in European countries.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The chronic liver disease market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Chronic Liver Disease Market Segmentation
By Treatment
By Disease Type
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Cancer
- Genetic Disorders
- Others
By Diagnosis Techniques
- Laboratory Tests
- Imaging
- Endoscopy
- Biopsy
- Others
By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgery Centers
- Others
Frequently Asked Questions
The Chronic Liver Disease market was valued at USD 22,143 million in 2022 and is expected to grow at a 7% CAGR over the forecast period 2023 – 2029.
The emerging markets, increase in unmet healthcare needs, and improved healthcare infrastructure are the key opportunities for the Chronic Liver Disease market.
The increasing prevalence and incidences of chronic liver diseases and increasing product launches and approvals are the growth drivers in the Chronic Liver Disease market.
Abbott Laboratories, Astellas Pharma Inc., Bristol-Myers Squibb Company, Gilead Sciences, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi AG, AbbVie Inc., Endo International PLC, Pfizer Inc., and Takeda Pharmaceutical are a few companies operating in the Chronic Liver Disease market.
| 1.Executive Summary |
| 2.Global Chronic Liver Disease Market Introduction |
| 2.1.Global Chronic Liver Disease Market - Taxonomy |
| 2.2.Global Chronic Liver Disease Market - Definitions |
| 2.2.1.Treatment |
| 2.2.2.Disease Type |
| 2.2.3.Diagnosis Techniques |
| 2.2.4.End User |
| 2.2.5.Region |
| 3.Global Chronic Liver Disease Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Chronic Liver Disease Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Chronic Liver Disease Market By Treatment, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Antiviral Drugs |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Immunosuppressant’s |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vaccines |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Immunoglobulin’s |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Corticosteroids, |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Targeted Therapy |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Chemotherapy |
| 5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6.Global Chronic Liver Disease Market By Disease Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Hepatitis |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Autoimmune Diseases |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Non-alcoholic Fatty Liver Disease (NAFLD) |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Cancer |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Genetic Disorders |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Chronic Liver Disease Market By Diagnosis Techniques, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Laboratory Tests |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Imaging |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Endoscopy |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Biopsy |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.Global Chronic Liver Disease Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Specialty Clinics |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Ambulatory Surgery Centers |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Others |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9.Global Chronic Liver Disease Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Chronic Liver Disease Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antiviral Drugs |
| 10.1.2.Immunosuppressant’s |
| 10.1.3.Vaccines |
| 10.1.4.Immunoglobulin’s |
| 10.1.5.Corticosteroids, |
| 10.1.6.Targeted Therapy |
| 10.1.7.Chemotherapy |
| 10.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hepatitis |
| 10.2.2.Autoimmune Diseases |
| 10.2.3.Non-alcoholic Fatty Liver Disease (NAFLD) |
| 10.2.4.Cancer |
| 10.2.5.Genetic Disorders |
| 10.2.6.Others |
| 10.3. Diagnosis Techniques Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Laboratory Tests |
| 10.3.2.Imaging |
| 10.3.3.Endoscopy |
| 10.3.4.Biopsy |
| 10.3.5.Others |
| 10.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospitals |
| 10.4.2.Specialty Clinics |
| 10.4.3.Ambulatory Surgery Centers |
| 10.4.4.Others |
| 10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Chronic Liver Disease Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antiviral Drugs |
| 11.1.2.Immunosuppressant’s |
| 11.1.3.Vaccines |
| 11.1.4.Immunoglobulin’s |
| 11.1.5.Corticosteroids, |
| 11.1.6.Targeted Therapy |
| 11.1.7.Chemotherapy |
| 11.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hepatitis |
| 11.2.2.Autoimmune Diseases |
| 11.2.3.Non-alcoholic Fatty Liver Disease (NAFLD) |
| 11.2.4.Cancer |
| 11.2.5.Genetic Disorders |
| 11.2.6.Others |
| 11.3. Diagnosis Techniques Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Laboratory Tests |
| 11.3.2.Imaging |
| 11.3.3.Endoscopy |
| 11.3.4.Biopsy |
| 11.3.5.Others |
| 11.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospitals |
| 11.4.2.Specialty Clinics |
| 11.4.3.Ambulatory Surgery Centers |
| 11.4.4.Others |
| 11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12.Asia Pacific (APAC) Chronic Liver Disease Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antiviral Drugs |
| 12.1.2.Immunosuppressant’s |
| 12.1.3.Vaccines |
| 12.1.4.Immunoglobulin’s |
| 12.1.5.Corticosteroids, |
| 12.1.6.Targeted Therapy |
| 12.1.7.Chemotherapy |
| 12.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hepatitis |
| 12.2.2.Autoimmune Diseases |
| 12.2.3.Non-alcoholic Fatty Liver Disease (NAFLD) |
| 12.2.4.Cancer |
| 12.2.5.Genetic Disorders |
| 12.2.6.Others |
| 12.3. Diagnosis Techniques Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Laboratory Tests |
| 12.3.2.Imaging |
| 12.3.3.Endoscopy |
| 12.3.4.Biopsy |
| 12.3.5.Others |
| 12.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospitals |
| 12.4.2.Specialty Clinics |
| 12.4.3.Ambulatory Surgery Centers |
| 12.4.4.Others |
| 12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Chronic Liver Disease Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Antiviral Drugs |
| 13.1.2.Immunosuppressant’s |
| 13.1.3.Vaccines |
| 13.1.4.Immunoglobulin’s |
| 13.1.5.Corticosteroids, |
| 13.1.6.Targeted Therapy |
| 13.1.7.Chemotherapy |
| 13.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Hepatitis |
| 13.2.2.Autoimmune Diseases |
| 13.2.3.Non-alcoholic Fatty Liver Disease (NAFLD) |
| 13.2.4.Cancer |
| 13.2.5.Genetic Disorders |
| 13.2.6.Others |
| 13.3. Diagnosis Techniques Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Laboratory Tests |
| 13.3.2.Imaging |
| 13.3.3.Endoscopy |
| 13.3.4.Biopsy |
| 13.3.5.Others |
| 13.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospitals |
| 13.4.2.Specialty Clinics |
| 13.4.3.Ambulatory Surgery Centers |
| 13.4.4.Others |
| 13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Chronic Liver Disease Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 14.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Antiviral Drugs |
| 14.1.2.Immunosuppressant’s |
| 14.1.3.Vaccines |
| 14.1.4.Immunoglobulin’s |
| 14.1.5.Corticosteroids, |
| 14.1.6.Targeted Therapy |
| 14.1.7.Chemotherapy |
| 14.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Hepatitis |
| 14.2.2.Autoimmune Diseases |
| 14.2.3.Non-alcoholic Fatty Liver Disease (NAFLD) |
| 14.2.4.Cancer |
| 14.2.5.Genetic Disorders |
| 14.2.6.Others |
| 14.3. Diagnosis Techniques Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Laboratory Tests |
| 14.3.2.Imaging |
| 14.3.3.Endoscopy |
| 14.3.4.Biopsy |
| 14.3.5.Others |
| 14.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospitals |
| 14.4.2.Specialty Clinics |
| 14.4.3.Ambulatory Surgery Centers |
| 14.4.4.Others |
| 14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Abbott Laboratories |
| 15.2.2.Astellas Pharma Inc. |
| 15.2.3.Bristol-Myers Squibb Company |
| 15.2.4.Gilead Sciences |
| 15.2.5.GlaxoSmithKline PLC |
| 15.2.6.Hoffmann-La Roche Ltd. |
| 15.2.7.Merck & Co. Inc. |
| 15.2.8.Novartis AG |
| 15.2.9.Sanofi AG |
| 15.2.10.AbbVie Inc. |
| 15.2.11.Endo International PLC |
| 15.2.12.Pfizer Inc. |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Abbott Laboratories
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Gilead Sciences
- GlaxoSmithKline PLC
- Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi AG
- AbbVie Inc.
- Endo International PLC
- Pfizer Inc.
- Takeda Pharmaceutical
- Alnylam Pharmaceuticals Inc.
- Provectus Biopharmaceuticals Inc.